Innovative approaches to treat pancreatic cancer
Official title: Washington University SPORE in Pancreatic Cancer
Funded at Washington University · NIH-10916333 · Data updated 2026-11-12
This study is working to find better ways to diagnose and treat pancreatic cancer by bringing together experts to develop new treatments and improve care for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 28, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,091,214 |
| NIH project number | 5P50CA272213-02 |
| Project ID | NIH-10916333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking novel treatment options.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), the most lethal form of pancreatic cancer. It brings together experts in immunology, cancer biology, and drug development to create new diagnostic and therapeutic strategies. The program includes multiple research projects and shared resources aimed at improving patient outcomes through innovative clinical trials. By leveraging advanced techniques in genomics and biostatistics, the team aims to develop targeted therapies that can significantly impact the treatment landscape for PDAC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved survival rates for patients with pancreatic cancer.
How similar studies have gone: Previous research in immunologic therapies for pancreatic cancer has shown promise, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.